IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CASALI, PAOLO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.141
NA - Nord America 7.014
AS - Asia 3.115
SA - Sud America 122
OC - Oceania 84
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 6
Totale 21.511
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.821
DE - Germania 3.904
GB - Regno Unito 3.680
CN - Cina 2.044
IT - Italia 1.240
SE - Svezia 685
IE - Irlanda 364
FR - Francia 303
IN - India 280
HK - Hong Kong 165
JP - Giappone 164
FI - Finlandia 158
ES - Italia 150
CA - Canada 148
SG - Singapore 107
NL - Olanda 87
GR - Grecia 83
BE - Belgio 82
KR - Corea 82
AU - Australia 78
DK - Danimarca 71
UA - Ucraina 61
RU - Federazione Russa 59
TR - Turchia 58
CH - Svizzera 51
TW - Taiwan 44
BR - Brasile 42
PL - Polonia 33
ID - Indonesia 32
MX - Messico 32
AT - Austria 28
CO - Colombia 25
PT - Portogallo 25
PH - Filippine 24
RO - Romania 23
VN - Vietnam 22
IL - Israele 20
CL - Cile 17
PE - Perù 15
AR - Argentina 14
TH - Thailandia 13
CZ - Repubblica Ceca 10
NO - Norvegia 10
UZ - Uzbekistan 10
EG - Egitto 9
MK - Macedonia 8
EU - Europa 7
PK - Pakistan 7
BG - Bulgaria 6
CU - Cuba 6
LB - Libano 6
SA - Arabia Saudita 6
ZA - Sudafrica 6
AE - Emirati Arabi Uniti 5
BD - Bangladesh 5
IR - Iran 5
NZ - Nuova Zelanda 5
SK - Slovacchia (Repubblica Slovacca) 5
EC - Ecuador 4
HU - Ungheria 4
MY - Malesia 4
VE - Venezuela 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BA - Bosnia-Erzegovina 3
GT - Guatemala 3
HR - Croazia 3
MU - Mauritius 3
QA - Qatar 3
AP - ???statistics.table.value.countryCode.AP??? 2
KZ - Kazakistan 2
MA - Marocco 2
NG - Nigeria 2
NP - Nepal 2
SC - Seychelles 2
AL - Albania 1
AM - Armenia 1
BZ - Belize 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
HN - Honduras 1
LU - Lussemburgo 1
LV - Lettonia 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
MZ - Mozambico 1
NC - Nuova Caledonia 1
OM - Oman 1
PS - Palestinian Territory 1
PY - Paraguay 1
SI - Slovenia 1
TN - Tunisia 1
ZW - Zimbabwe 1
Totale 21.517
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 3.511
Southend 3.473
Chandler 767
Fairfield 736
Seattle 565
Milan 528
Princeton 428
Ashburn 420
Wilmington 415
Dublin 360
Houston 345
Woodbridge 333
Cambridge 282
Beijing 277
Ann Arbor 238
Dearborn 216
Nanjing 213
Redwood City 201
Des Moines 164
Guangzhou 152
Hangzhou 144
Bengaluru 110
Jinan 102
Phoenix 96
Shanghai 96
Hong Kong 95
Shenyang 87
Toronto 87
Boardman 81
Munich 76
Nanchang 70
Changsha 60
Helsinki 53
Tokyo 53
Hebei 49
San Diego 46
Central District 45
Brussels 41
Madrid 40
Tianjin 39
London 38
New York 38
Singapore 36
Jiaxing 34
Zhengzhou 32
Rome 31
Taipei 31
Los Angeles 27
Seoul 27
Berlin 26
Redmond 25
Silver Spring 25
Haikou 24
Mountain View 24
Pune 24
Wuhan 24
Andover 22
Taizhou 22
Chicago 21
Lubbock 21
Rho 21
Turin 21
Hefei 20
Ottawa 19
Canberra 18
Falls Church 18
Fuzhou 18
Paris 18
Tappahannock 18
Amsterdam 17
Kunming 17
Bologna 16
Lanzhou 16
San Francisco 16
Chengdu 15
Duncan 15
Sydney 15
Bogotá 14
Chongqing 14
Grafing 13
Leiden 13
Ningbo 13
Taiyuan 13
Barcelona 12
Fremont 12
Jacksonville 12
Naples 12
Bühl 11
Lima 11
Ankara 10
Atlanta 10
Istanbul 10
Mcallen 10
Roxbury 10
Seongnam 10
São Paulo 10
Torino 10
Columbus 9
Groningen 9
Medford 9
Totale 16.201
Salva come PNG Salva come JPEG
Nome #
Global cancer control: responding to the growing burden, rising costs and inequalities in access 733
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up 694
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment : a non-randomised phase 2 clinical trial 612
Biosimilars : a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers 595
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up 583
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up 435
High-grade soft-tissue sarcomas: Tumor response assessment - Pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria 377
How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience 317
Primary extremity soft tissue sarcomas: Outcome improvement over time at a single institution 296
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 278
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113) 233
NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas 214
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups 213
Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma 178
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma 177
Response to sunitinib malate in advanced alveolar soft part sarcoma 171
Best practices for the management of local-regional recurrent chordoma : a position paper by the Chordoma Global Consensus Group 168
Solitary fibrous tumour presenting with a single bone metastasis : report of six cases and literature review 166
Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial 161
Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study 157
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma 150
Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas 147
The GOLD ReGISTry: A Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours 146
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors 145
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST 144
Imatinib mesylate in chordoma 143
Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients 141
High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma 140
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake 138
2018 ESMO Sarcoma and GIST Symposium: take-home messages' in soft tissue sarcoma 137
Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor 135
Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue 135
Identification of a gene expression driven progression pathway in Myxoid liposarcoma 133
Evaluating the effectiveness of clinical ethics committees : a systematic review 133
Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib 132
ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma : a critical review 129
Identification of an actionable mutation of kit in a case of extraskeletal myxoid chondrosarcoma 129
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells 128
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers : a European consensus position paper 128
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment 128
Guidelines for time-to-event endpoint definitions in sarcomas and gastro-intestinal stromal tumors (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) 128
Mode of action of trabectedin in myxoid liposarcomas 127
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient [3] 126
Histology-Specific Nomogram for Primary Retroperitoneal Soft Tissue Sarcoma 125
PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study 123
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma : A Multicenter, International, Retrospective Study 121
The management of desmoid tumours : A joint global consensus-based guideline approach for adult and paediatric patients 121
Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas) 119
Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib : a case report 118
Analyzing the "careGap" : assessing gaps in adherence to clinical guidelines in adult soft tissue sarcoma 117
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas 117
Quality of life assessment and clinical decision-making 115
Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers 114
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 112
Epithelioid peritoneal mesothelioma : a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework 111
Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre : Should Radiotherapy Still be a Standard? 111
Role of macrophage targeting in the antitumor activity of trabectedin 109
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors? 108
Data protection and research in the European Union: a major step forward, with a step back 108
Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients—A propensity score analysis 107
Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study 106
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST : a retrospective analysis 104
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS) : long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group 104
The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors : A Multicenter, European Retrospective Case Series Analysis 104
Localised thoracic sarcomas : outcome improvement over time at a single institution 103
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 102
Dacarbazine in solitary fibrous tumor : a case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics 102
Sporadic desmoid-type fibromatosis: A stepwise approach to a non-metastasising neoplasm-A position paper from the Italian and the French Sarcoma Group 101
The off-label use of drugs in oncology: A position paper by the European Society for Medical Oncology (ESMO) 100
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma : revisiting the results of the EORTC-STBSG 62931 randomised trial 95
Objective and rational evaluation of the quality of life in oncology in the first phase of the QVONC project 94
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trial 93
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 93
Risks of the new EU Data protection regulation : an ESMO position paper endorsed by the European oncology community 93
Current models, challenges and best practices for work conducted between European academic cooperative groups and industry 90
Activity of sunitinib in extraskeletal myxoid chondrosarcoma 89
Adjuvant chemotherapy for soft tissue sarcoma 89
Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma : a multi-institutional case series 89
Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy 88
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour 88
Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts 88
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 87
Comparative assessment of antitumor effects and autophagy induction as a resistance mechanism by cytotoxics and EZH2 inhibition in INI1-negative epithelioid sarcoma patient-derived xenograft 87
High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial 86
The current and future role of the medical oncologist in the professional care for cancer patients : a position paper by the European Society for Medical Oncology (ESMO) 85
External validation of a multi-institutional retroperitoneal sarcoma nomogram 85
Head and neck soft tissue sarcomas : prognostic factors and outcome in a series of patients treated at a single institution 85
Hope in cancer patients : The relational domain as a crucial factor 84
Rare cancers : work in progress in Europe 84
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 83
Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303 83
Adjuvant imatinib for GI stromal tumors : when and for how long? 82
Pazopanib for treatment of typical solitary fibrous tumours : a multicentre, single-arm, phase 2 trial 82
Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS) : a report on 1007 patients from the multi-institutional collaborative RPS working group 81
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study 81
Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian rare cancer network 81
Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors 80
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas 79
Sporadic extra abdominal wall desmoid-type fibromatosis : surgical resection can be safely limited to a minority of patients 79
Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: A case series analysis and literature review 79
Totale 15.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.982
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.982
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019694 0 0 0 0 0 0 0 0 0 0 338 356
2019/20204.340 506 226 241 527 363 535 491 301 403 377 161 209
2020/20213.436 172 222 239 189 331 270 459 383 424 266 311 170
2021/20222.526 198 205 135 130 193 170 138 190 232 209 170 556
2022/20233.032 402 306 333 291 313 539 92 169 279 63 164 81
2023/20245.082 114 158 134 136 454 242 1.168 996 513 1.007 160 0
Totale 22.923